However, 28% of all GSD patients diagnosed with hepatocellular adenoma display mutations in CTNNB1, which accelerate the metabolic phenotype and the malignant transformation towards HCC [30]. This evidence concerns the gene CTNNB1 and hepatocellular adenoma.